{"id":"androstenedione","rwe":[],"tags":[{"label":"androstenedione","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Aromatase","category":"target"},{"label":"CYP19A1","category":"gene"},{"label":"SHBG","category":"gene"},{"label":"HSD17B3","category":"gene"},{"label":"Active","category":"status"}],"phase":"unknown","safety":{"commonSideEffects":[]},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":"fecundin","offLabel":[],"synonyms":["androstenedione","fecundin","4-Androstene-3,17-dione"],"timeline":[],"brandName":"Fecundin","ecosystem":[],"mechanism":{"target":"Corticosteroid-binding globulin, Alpha-synuclein, Sex hormone-binding globulin","targets":[{"gene":"CYP19A1","source":"DrugCentral","target":"Aromatase","protein":"Aromatase"},{"gene":"SHBG","source":"DrugCentral","target":"Sex hormone-binding globulin","protein":"Sex hormone-binding globulin"},{"gene":"HSD17B3","source":"DrugCentral","target":"Testosterone 17-beta-dehydrogenase 3","protein":"Testosterone 17-beta-dehydrogenase 3"},{"gene":"SERPINA6","source":"DrugCentral","target":"Corticosteroid-binding globulin","protein":"Corticosteroid-binding globulin"},{"gene":"SNCA","source":"DrugCentral","target":"Alpha-synuclein","protein":"Alpha-synuclein"}],"modality":"Small Molecule","drugClass":"androstenedione","explanation":"Think of aromatase like a factory that produces estrogen. Fecundin is a key that blocks the factory's door, preventing estrogen from being made. This can be helpful in certain medical conditions, but it's a complex process that requires careful consideration.","oneSentence":"Fecundin works by binding to the aromatase enzyme and inhibiting its activity, which can lead to a decrease in estrogen production.","technicalDetail":"Fecundin acts as a competitive inhibitor of the aromatase enzyme, specifically targeting the heme-containing active site and preventing the conversion of androgen precursors to estrogen."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/215","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=androstenedione","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=androstenedione","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T08:47:59.063901","biosimilars":[],"competitors":[{"drugName":"aminoglutethimide","drugSlug":"aminoglutethimide","fdaApproval":"1980-10-29","patentStatus":"Unknown","relationship":"same-target"},{"drugName":"anastrozole","drugSlug":"anastrozole","fdaApproval":"1995-12-27","genericCount":19,"patentStatus":"Off-patent — generic available","relationship":"same-target"},{"drugName":"clotrimazole","drugSlug":"clotrimazole","fdaApproval":"1975-02-03","patentExpiry":"May 26, 2042","patentStatus":"Patent protected","relationship":"same-target"},{"drugName":"doconexent","drugSlug":"doconexent","fdaApproval":"","relationship":"same-target"},{"drugName":"eicosapentaenoic acid","drugSlug":"eicosapentaenoic-acid","fdaApproval":"","relationship":"same-target"},{"drugName":"estrone","drugSlug":"estrone","fdaApproval":"1979-02-21","genericCount":3,"patentStatus":"Off-patent — generic available","relationship":"same-target"},{"drugName":"exemestane","drugSlug":"exemestane","fdaApproval":"1999-10-21","genericCount":11,"patentStatus":"Off-patent — generic available","relationship":"same-target"},{"drugName":"fluorouracil","drugSlug":"fluorouracil","fdaApproval":"1962-04-25","genericCount":23,"patentStatus":"Off-patent — generic available","relationship":"same-target"},{"drugName":"ketoconazole","drugSlug":"ketoconazole","fdaApproval":"1981-06-12","genericCount":19,"patentStatus":"Off-patent — generic available","relationship":"same-target"},{"drugName":"letrozole","drugSlug":"letrozole","fdaApproval":"1997-07-25","genericCount":19,"patentStatus":"Off-patent — generic available","relationship":"same-target"}],"dataSources":[{"url":"https://drugcentral.org","name":"DrugCentral","fields":["indications","contraindications","safety","target","drugInteractions"],"retrievedDate":"2026-04-07"}],"genericName":"androstenedione","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"aminoglutethimide","brandName":"aminoglutethimide","genericName":"aminoglutethimide","approvalYear":"1980","relationship":"same-target"},{"drugId":"anastrozole","brandName":"anastrozole","genericName":"anastrozole","approvalYear":"1995","relationship":"same-target"},{"drugId":"clotrimazole","brandName":"clotrimazole","genericName":"clotrimazole","approvalYear":"1975","relationship":"same-target"},{"drugId":"doconexent","brandName":"doconexent","genericName":"doconexent","approvalYear":"","relationship":"same-target"},{"drugId":"eicosapentaenoic-acid","brandName":"eicosapentaenoic acid","genericName":"eicosapentaenoic acid","approvalYear":"","relationship":"same-target"},{"drugId":"estrone","brandName":"estrone","genericName":"estrone","approvalYear":"1979","relationship":"same-target"},{"drugId":"exemestane","brandName":"exemestane","genericName":"exemestane","approvalYear":"1999","relationship":"same-target"},{"drugId":"fluorouracil","brandName":"fluorouracil","genericName":"fluorouracil","approvalYear":"1962","relationship":"same-target"},{"drugId":"ketoconazole","brandName":"ketoconazole","genericName":"ketoconazole","approvalYear":"1981","relationship":"same-target"},{"drugId":"letrozole","brandName":"letrozole","genericName":"letrozole","approvalYear":"1997","relationship":"same-target"}],"trialDetails":[{"nctId":"NCT05555680","phase":"","title":"Effect of Hyperandrogenism on IVF Outcomes in PCOS Patients","status":"TERMINATED","sponsor":"Clinique Ovo","startDate":"2022-01-21","conditions":["PCOS (Polycystic Ovary Syndrome) of Bilateral Ovaries"],"enrollment":32,"completionDate":"2025-01-29"},{"nctId":"NCT05623397","phase":"","title":"A Deep Learning Method to Evaluate QT on Ribociclib","status":"COMPLETED","sponsor":"CMC Ambroise Paré","startDate":"2023-07-28","conditions":["Breast Cancer","Ribociclib"],"enrollment":70,"completionDate":"2025-10-08"},{"nctId":"NCT02574910","phase":"PHASE1","title":"Androgen Reduction in Congenital Adrenal Hyperplasia, Phase 1","status":"TERMINATED","sponsor":"University of Texas Southwestern Medical Center","startDate":"2017-08-01","conditions":["Congenital Adrenal Hyperplasia"],"enrollment":4,"completionDate":"2023-06-03"},{"nctId":"NCT05293366","phase":"","title":"LOng COvid COmorbidities: Endocrine,Metabolic,Neuropsychiatric,Muscle,Cardiovascular,Pulmonary,Dermatologic Dysfunctions","status":"RECRUITING","sponsor":"Federico II University","startDate":"2022-01-27","conditions":["Long Covid-19"],"enrollment":100,"completionDate":"2027-01-27"},{"nctId":"NCT06729359","phase":"","title":"Polycystic Ovary Syndrome and Urinary Tract Stones: a BMI-Adjusted Analysis in Iraqi Women","status":"COMPLETED","sponsor":"Al-Kindy College of Medicine","startDate":"2024-07-01","conditions":["PCOS (Polycystic Ovary Syndrome)","Stone, Urinary","BMI","Obesity","Overweight","Underweight"],"enrollment":407,"completionDate":"2024-11-15"},{"nctId":"NCT03477396","phase":"PHASE2","title":"Ribociclib and Aromatase Inhibitor in Treating Older Participants With Hormone Receptor Positive Metastatic Breast Cancer","status":"COMPLETED","sponsor":"City of Hope Medical Center","startDate":"2018-06-14","conditions":["Estrogen Receptor and/or Progesterone Receptor Positive","HER2/Neu Negative","Stage IV Breast Cancer AJCC v6 and v7"],"enrollment":2,"completionDate":"2023-06-05"},{"nctId":"NCT05903716","phase":"","title":"The Effects of Systemic Isotretinoin Treatment on Adrenal Steroid and Sex Hormones Level in Severe Acne Vulgaris","status":"UNKNOWN","sponsor":"Marmara University","startDate":"2022-09-15","conditions":["Acne Vulgaris"],"enrollment":40,"completionDate":"2023-06-30"},{"nctId":"NCT05811507","phase":"","title":"Evaluation of Serum Adrenal Androgens Among Prepubertal and Pubertal Boys With Autism Spectrum Disorder","status":"UNKNOWN","sponsor":"Sohag University","startDate":"2023-04","conditions":["Autism Spectrum Disorder"],"enrollment":100,"completionDate":"2024-04"},{"nctId":"NCT04979091","phase":"","title":"Sex Hormone Dysregulations Are Associated With Critical Illness in COVID-19 Patients","status":"COMPLETED","sponsor":"Universitätsklinikum Hamburg-Eppendorf","startDate":"2020-03-08","conditions":["Covid19","Critical Illness"],"enrollment":100,"completionDate":"2021-05-31"},{"nctId":"NCT03578497","phase":"PHASE2","title":"Effects of Interleukin-1 Receptor Antagonism on Hyperandrogenemia in Women With Polycystic Ovary Syndrome","status":"COMPLETED","sponsor":"University Hospital, Basel, Switzerland","startDate":"2018-08-31","conditions":["Polycystic Ovary Syndrome"],"enrollment":18,"completionDate":"2020-07-30"},{"nctId":"NCT03447184","phase":"","title":"Long-term Endogenous Androgen Priming in Bologna Criteria Poor Responder Patients - A Pilot Study","status":"COMPLETED","sponsor":"Mỹ Đức Hospital","startDate":"2018-03-26","conditions":["Poor Ovarian Response"],"enrollment":30,"completionDate":"2019-03-01"},{"nctId":"NCT02329483","phase":"","title":"Monitoring the Early Follicular Phase With Androstenedione in Low-dose Step-up Ovulation Induction in High Responders","status":"UNKNOWN","sponsor":"Bagcilar Training and Research Hospital","startDate":"2014-12","conditions":["Infertility","Ovarian Hyperstimulation Syndrome"],"enrollment":50,"completionDate":"2015-06"},{"nctId":"NCT01817400","phase":"EARLY_PHASE1","title":"Mediators of Abnormal Reproductive Function in Obesity (MARO)","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2013-03","conditions":["Infertility, Female","Obesity"],"enrollment":10,"completionDate":"2014-12"},{"nctId":"NCT01495910","phase":"PHASE1","title":"A Study Examining Doses of Abiraterone Acetate in Adult Women With 21-Hydroxylase Deficiency","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2011-12","conditions":["21-hydroxylase Deficiency"],"enrollment":6,"completionDate":"2013-02"},{"nctId":"NCT01940666","phase":"","title":"Presentations of Hyperandrogenic Phenotypes in Taiwanese Women","status":"COMPLETED","sponsor":"Taipei Medical University WanFang Hospital","startDate":"2012-09","conditions":["Hyperandrogenism,","Polycystic Ovary Syndrome,","Metabolic Syndrome,","Insulin Resistance,","Cardiovascular Disease."],"enrollment":649,"completionDate":"2013-07"},{"nctId":"NCT00334971","phase":"NA","title":"Aromatase Activity and Ovarian Growth Factors in African-American Versus Caucasian Women","status":"UNKNOWN","sponsor":"Massachusetts General Hospital","startDate":"2004-09","conditions":["Healthy","Fragile X Syndrome"],"enrollment":116,"completionDate":"2018-01"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{},"crossReferences":{"NUI":"N0000148795","NDDF":"011070","UNII":"409J2J96VR","VUID":"4021377","CHEBI":"CHEBI:16422","VANDF":"4021377","RXNORM":"784","UMLSCUI":"C0002860","ChEMBL_ID":"CHEMBL274826","KEGG_DRUG":"D00051","DRUGBANK_ID":"DB01536","PDB_CHEM_ID":"ASD","PUBCHEM_CID":"6128","SNOMEDCT_US":"56146000","IUPHAR_LIGAND_ID":"2860","MESH_DESCRIPTOR_UI":"D000735","MESH_SUPPLEMENTAL_RECORD_UI":"C042013"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":10389,"therapeuticAreas":["Other"],"biosimilarFilings":[],"recentPublications":[],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"unknown","modality":"Small Molecule","firstApprovalDate":"","aiSummary":"Fecundin, also known as androstenedione, is a small molecule drug that targets aromatase. It is classified as an androstenedione, but its commercial status and approved indications are unknown. As a small molecule, it is designed to interact with the aromatase enzyme, which is involved in the production of estrogen. The exact mechanism of action and safety considerations of Fecundin are unclear due to a lack of publicly available information. Further research is needed to fully understand its potential therapeutic applications and risks.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}